ClinicalTrials.gg
CompletedNCT03051100Updated Apr 3, 2020Results posted

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

A Phase 2 interventional study of Bempedoic acid 180mg and Ezetimibe 10mg in Hypercholesterolemia, sponsored by Esperion Therapeutics, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-03.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.

Enrollment
15th of 21
63 · median 126
Started
2017
with 3 others
Phase 2
10 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
15 of 21
Esperion Therapeutics, Inc.

Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 15th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 11th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About bempedoic acid

bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bempedoic acid in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • hyperlididemia
  • LDL
  • cholesterol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting LDL-cholesterol between 130 - 189 mg/dL at screening following washout of all LDL-C-lowering drugs and nutritional supplements
  • Men and nonpregnant, nonlactating women
  • Sufficiently stable and suitable to undergo washout of all LDL-C-lowering drugs and nutritional supplements for 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Fasting blood triglycerides greater than or equal to 400 mg/dL
  • (BMI) greater than 50 kg/m2
  • History of cardiovascular disease
  • History of type 1 or type 2 diabetes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Triplet Therapy

    Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.

    Drug: Bempedoic acid 180mg · Drug: Ezetimibe 10mg · Drug: Atorvastatin 20mg

  • Placebo comparator
    placebo

    Matching placebos taken orally, daily.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6

    Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the values from Week -1 (Screening Visit 2) and predose Day 1/Week 0 (Treatment Visit 1). Percent change from Baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group as a factor and Baseline value as a covariate. Missing LDL-C values were imputed using last observation carried forward (LOCF), with only post-Baseline values carried forward. If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.

    Time frame: Baseline; Week 6

Secondary outcomes

  1. Percent Change From Baseline in Lipid Profile Parameters at Week 6

    Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the values from Week -1 (Screening Visit 2) and predose Day 1/Week 0 (Treatment Visit 1). Baseline apolipoprotein B (apoB) was measured only at predose/Day 1. Percent change from Baseline was analyzed using analysis of covariance (ANCOVA) with treatment group as a factor and Baseline value as a covariate. Missing values were imputed using LOCF, with only post-Baseline values carried forward. non-HDL-C, non-high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.

    Time frame: Baseline; Week 6

  2. Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 6

    Percent change is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the predose Day 1/Week 0 (Treatment Visit 1) value. If only one value is available either at Week -1 (Screening Visit 2) or Week 0 (Treatment Visit 1), then that value is used as Baseline. Missing values were imputed using LOCF, with only post-Baseline values carried forward.

    Time frame: Baseline; Week 6

  3. Number of Participants With LDL-C <70 mg/dL at Week 6

    Analysis was based on LOCF values. If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.

    Time frame: Week 6

  4. Number of Participants With LDL-C Reduction ≥50% From Baseline at Week 6

    If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.

    Time frame: Baseline; Week 6

07

Results

Posted Apr 3, 2020

Participant flow

Participant flow — Overall Study
MilestonePlaceboTriplet Therapy
Started2043
Completed1943
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6

Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the values from Week -1 (Screening Visit 2) and predose Day 1/Week 0 (Treatment Visit 1). Percent change from Baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group as a factor and Baseline value as a covariate. Missing LDL-C values were imputed using last observation carried forward (LOCF), with only post-Baseline values carried forward. If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.

Time frame:
Baseline; Week 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6
percent changePlaceboTriplet Therapy
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6-3.1 ± 3.27-63.6 ± 1.67
Statistical analysis
  • Placebo vs Triplet Therapy · ANCOVA · p = <0.001 · Least squares mean difference: -60.5 · 95% CI -68.0 to -53.0Triplet therapy minus placebo
SecondaryPercent Change From Baseline in Lipid Profile Parameters at Week 6

Percent change from Baseline is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the mean of the values from Week -1 (Screening Visit 2) and predose Day 1/Week 0 (Treatment Visit 1). Baseline apolipoprotein B (apoB) was measured only at predose/Day 1. Percent change from Baseline was analyzed using analysis of covariance (ANCOVA) with treatment group as a factor and Baseline value as a covariate. Missing values were imputed using LOCF, with only post-Baseline values carried forward. non-HDL-C, non-high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.

Time frame:
Baseline; Week 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Lipid Profile Parameters at Week 6
percent changePlaceboTriplet Therapy
non-HDL-C-1.3 ± 2.56-60.0 ± 1.60
TC-1.1 ± 2.24-47.1 ± 1.63
apoB0.6 ± 2.24-53.5 ± 1.57
TG8.9 ± 5.95-27.4 ± 2.79
HDL-C0.4 ± 2.26-1.1 ± 1.47
Statistical analysis
  • Placebo vs Triplet Therapy · ANCOVA · p = <0.001 · Least squares mean difference: -58.7 · 95% CI -64.9 to -52.6Triplet therapy minus placebo
  • Placebo vs Triplet Therapy · ANCOVA · p = <0.001 · Least squares mean difference: -46.0 · 95% CI -51.6 to -40.4Triplet therapy minus placebo
  • Placebo vs Triplet Therapy · ANCOVA · p = <0.001 · Least squares mean difference: -54.1 · 95% CI -59.7 to -48.6
  • Placebo vs Triplet Therapy · ANCOVA · p = <0.001 · Least squares mean difference: -36.3 · 95% CI -49.7 to -22.8
  • Placebo vs Triplet Therapy · ANCOVA · p = =0.588 · Least squares mean difference: -1.5 · 95% CI -7.0 to 4.0
SecondaryPercent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 6

Percent change is calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value ) x 100. Baseline is defined as the predose Day 1/Week 0 (Treatment Visit 1) value. If only one value is available either at Week -1 (Screening Visit 2) or Week 0 (Treatment Visit 1), then that value is used as Baseline. Missing values were imputed using LOCF, with only post-Baseline values carried forward.

Time frame:
Baseline; Week 6
Reported as:
Median · percent change
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 6
percent changePlaceboTriplet Therapy
Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 6-2.7 (-19.8 to 17.9)-47.7 (-66.0 to -22.7)
Statistical analysis
  • Placebo vs Triplet Therapy · Wilcoxon rank sum test · p = <0.001 · Median treatment difference: -41.9 · 95% CI -60.0 to -21.4
SecondaryNumber of Participants With LDL-C <70 mg/dL at Week 6

Analysis was based on LOCF values. If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.

Time frame:
Week 6
Reported as:
Count of participants · Participants
Number of Participants With LDL-C <70 mg/dL at Week 6
ParticipantsPlaceboTriplet Therapy
Number of Participants With LDL-C <70 mg/dL at Week 6037
Statistical analysis
  • Placebo vs Triplet Therapy · Fisher Exact · p = <0.001
SecondaryNumber of Participants With LDL-C Reduction ≥50% From Baseline at Week 6

If LDL-C was measured (i.e., if TG was \>400 mg/dL or LDL-C was \<50 mg/dL), the measured values were used in the analysis.

Time frame:
Baseline; Week 6
Reported as:
Count of participants · Participants
Number of Participants With LDL-C Reduction ≥50% From Baseline at Week 6
ParticipantsPlaceboTriplet Therapy
Number of Participants With LDL-C Reduction ≥50% From Baseline at Week 6039
Statistical analysis
  • Placebo vs Triplet Therapy · Fisher Exact · p = <0.001

Adverse events

Collected over up to 6 weeks plus 30 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/20 (0%)0/20 (0%)7/20 (35%)
Triplet Therapy0/43 (0%)0/43 (0%)15/43 (34.9%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlaceboTriplet Therapy
Muscle spasmsMusculoskeletal and connective tissue disorders2/201/43
ArthralgiaMusculoskeletal and connective tissue disorders1/201/43
Back painMusculoskeletal and connective tissue disorders1/201/43
Joint swellingMusculoskeletal and connective tissue disorders1/200/43
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/200/43
HeadacheNervous system disorders1/202/43
DizzinessNervous system disorders1/201/43
FolliculitisInfections and infestations1/200/43
NauseaGastrointestinal disorders1/201/43
Ear painEar and labyrinth disorders1/200/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboTriplet TherapyTotal
Mean61.2 ± 7.7761.2 ± 12.2661.2 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTriplet TherapyTotal
Female142640
Male61723
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboTriplet TherapyTotal
American Indian or Alaska native011
Asian112
Black or African American3710
White163450
Baseline LDL-C, non-HDL-C, HDL-C, TC, and TG Values
Baseline LDL-C, non-HDL-C, HDL-C, TC, and TG Values(milligrams per deciliter (mg/dL))PlaceboTriplet TherapyTotal
LDL-C155.90 ± 13.749154.29 ± 17.913154.80 ± 16.609
non-HDL-C183.13 ± 18.363183.59 ± 27.347183.44 ± 24.698
HDL-C52.03 ± 12.97752.05 ± 12.93652.04 ± 12.844
TC235.13 ± 21.196235.67 ± 26.992235.50 ± 25.125
TG139.53 ± 62.475150.70 ± 81.375147.15 ± 75.560
Baseline Apolipoprotein B (apoB) Values
Baseline Apolipoprotein B (apoB) Values(mg/dL)PlaceboTriplet TherapyTotal
Mean119.2 ± 15.25118.0 ± 19.89118.4 ± 18.42
Baseline High-Sensitivity C-Reactive Protein (hs-CRP) Values
Baseline High-Sensitivity C-Reactive Protein (hs-CRP) Values(milligrams per Liter)PlaceboTriplet TherapyTotal
Median1.64 (0.12 to 9.51)1.94 (0.27 to 29.16)1.88 (0.12 to 29.16)
08

Study locations

11 sites
  • PMG Research of Christie Clinic
    Champaign, Illinois 61820, United States
  • PMG Research of Cary
    Cary, North Carolina 27518, United States
  • PMG Research of Charlotte
    Charlotte, North Carolina 28209, United States
  • Sensenbrenner Primary Care
    Charlotte, North Carolina 28277, United States
  • PMG Research of Hickory
    Hickory, North Carolina 28601, United States
  • PMG Research of Raleigh
    Raleigh, North Carolina 27609, United States
  • PMG Research of Rocky Mount
    Rocky Mount, North Carolina 27804, United States
  • PMG Research Salisbury
    Salisbury, North Carolina 28144, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • PMG Research of Charleston
    Mount Pleasant, South Carolina 29464, United States
  • Hampton Roads Center for Clinical Research
    Virginia Beach, Virginia 23451, United States
09

References and documents

Publications

  • Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28;7:13457. doi: 10.1038/ncomms13457. PubMed 27892461 ↗
  • Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep. 2016 Oct;18(10):61. doi: 10.1007/s11883-016-0611-4. PubMed 27663902 ↗
  • Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May-Jun;10(3):556-67. doi: 10.1016/j.jacl.2015.12.025. Epub 2016 Jan 6. PubMed 27206943 ↗
  • Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, Robinson PL, Hanselman JC, Lalwani ND. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. Am J Cardiol. 2016 Jun 15;117(12):1928-33. doi: 10.1016/j.amjcard.2016.03.043. Epub 2016 Apr 6. PubMed 27138185 ↗
  • Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, Newton RS. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May-Jun;9(3):295-304. doi: 10.1016/j.jacl.2015.03.003. Epub 2015 Mar 19. PubMed 26073387 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Jun 2017, 4 months.

Results were first posted in Apr 2020, 2 years 10 months after primary completion. A results delay was requested in Jul 2018.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2017
First posted
Feb 13, 2017
StartActual
Jan 19, 2017
Primary completionActual
Jun 1, 2017
CompletionActual
Jul 5, 2017
Results delay requested
Jul 23, 2018
Results first posted
Apr 3, 2020
Last update
Apr 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03051100
Responsible party
Sponsor
First posted
Feb 13, 2017
Start date
Jan 19, 2017
Primary completion
Jun 1, 2017
Completion
Jul 5, 2017
Results posted
Apr 3, 2020
Last update
Apr 3, 2020

Study contacts

Ron Haberman, MD
study director · Esperion Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion